24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
In manufacturing, signals often emerge far from marketing headlines, from cold-chain telemetry to procurement volatility. Right now, biopharmaceutical APIs are among the clearest, pushing facilities to rethink control strategies, analytical depth, and supply resilience across Russia and the CIS. For plants under pressure to raise yield, reduce deviations, and keep dossiers inspection-ready, the next generation of therapeutics is also the next generation of process discipline.
Biopharmaceutical APIs include recombinant proteins, monoclonal antibodies, peptides, oligonucleotides, and other biologically derived drug substances. Their value is clear: higher specificity, new modalities, and treatment routes that small molecules cannot always reach. Their manufacturing reality is also clear: more complex variability drivers, more sensitive impurity profiles, and tighter requirements for data integrity and traceability.
Regulators increasingly expect a clear link between critical quality attributes (CQAs), process understanding, and impurity control across the manufacturing lifecycle. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q11 sets expectations around the development and manufacture of drug substances, including how process knowledge and control strategies are presented in Module 3 of the CTD.
In biopharma, “test it at the end” is expensive and often too late. A robust control strategy starts upstream and continues through purification and finishing, with defined acceptance criteria, validated analytical methods, and a clear rationale for where GMP applies.
ICH Q7 remains the baseline for GMP expectations for API manufacturing and quality systems, including documentation, materials management, and change control. WHO GMP guidance similarly frames GMP as a quality management system focused on consistent production and control, reducing risks like mix-ups and contamination.
In practice, biopharmaceutical API manufacturers and their partners are prioritising:
Media quality, bioburden management, and tight parameter ranges (pH, dissolved oxygen, temperature, feed strategy) reduce purification burden and improve batch-to-batch consistency.
Impurity profiles in biologics can be process-dependent. Building a rationale for impurity clearance and linking it to step performance reduces both investigative burden and regulatory friction, particularly when scale-up or second-source materials require changes. ICH Q11 highlights the importance of understanding impurity formation, fate, and purge in drug-substance manufacturing.
Quality risk management principles help teams focus validation effort where it reduces risk the most, rather than spreading resources thinly across low-impact controls.
Manufacturers operating across the Eurasian Economic Union (EAEU) face a dual requirement: meet local frameworks while maintaining alignment with international expectations to support exports, partnerships, and technology transfer.
EAEU pharmaceutical inspection rules establish a unified procedure for GMP inspections across the Union, raising the bar on inspection readiness, documentation discipline, and site-wide quality culture. For QA, regulatory affairs, and plant leadership, the commercial implication is simple: compliance readiness affects time-to-market, supply continuity, and partner confidence.
Pharmtech & Ingredients is structured around the full pharmaceutical production lifecycle, from raw materials and APIs through processing, laboratories, packaging, and data integrity.
At the Pharmtech Expo (24-27 November 2026, Crocus Expo, Pavilion 2), we bring together technology and supplier options aligned with GMP, ISO expectations, and regional regulatory realities, with the added benefit of technical seminars that translate developments into implementation decisions.
To help teams plan efficiently, map your objectives to the relevant pharmaceutical exhibition sectors:
If you want to visit a pharma trade show with a focused agenda, start by listing your highest-cost constraints (deviations, yield loss, long changeovers, supplier risk) and use the show floor to validate which technologies and partners can reduce them.
For planning content and updates, check Pharmtech's latest news and arrange your team’s visit around the sessions and suppliers most relevant to your pipeline, whether you are evaluating a new CDMO partner, expanding biologics fill-finish capability, or improving upstream reliability. Many visitors treat it as their annual benchmark for pharma manufacturing: one place to compare approaches, documentation expectations, and real operating trade-offs.
Biopharmaceutical APIs demand tighter control strategies, stronger analytics, and smarter digital systems, but they also create opportunities for plants and partners to demonstrate consistency at scale. Pharmtech & Ingredients is where the Russia and CIS manufacturing community meets global suppliers and service providers to translate therapeutic progress into validated, production-ready reality.
Interested in exhibiting? Submit an enquiry to reserve your space in the Contract Services zone and showcase your compliance-ready capabilities to qualified production leaders, QA decision-makers, and procurement teams across Eurasia.
